The theme of this year's conference is "AD Drug Therapy: Hope and Reality, New Targets in Sight?

 

Research in AD drug therapy remains active and not only have new therapeutic approaches been developed, but most importantly also new definitions of Alzheimer's disease. The big question still remains what is the right patient population to test new drugs, when shall we start treating, what are the right targets and finally what will be the best compounds? At the moment there is agreement that treatment should start as early as possible which results in the challenge of reliable early diagnoses. New developments in imaging technologies including in vivo determination of brain amyloid using PET and research on CSF as well as blood biomarkers should support early diagnosis. Still we have to be clear that so far no longitudinal validation of new diagnostic criteria is available, but first clinical trials using this patient population are on the way and results can certainly be expected in the not too distant future.

 

We will at our meeting also discuss new , sensitive neuropsychological tests, which should enable a better translation from preclinical findings to the clinical trial situation

 

The meeting is limited to a maximum of 80 participants. Who comes first will be served first!